Clinical Study
Efficacy and Safety of Low-Dose Cyclosporine with Everolimus and Steroids in de novo Heart Transplant Patients: A Multicentre, Randomized Trial
Table 3
Incidence of efficacy events at Month 6. HDC, haemodynamic compromise.
| | RD CsA () | ST CsA () |
| | Composite efficacy failure (BPAR ≥3 A, acute rejection associated with HDC, death, graft loss/retransplant or lost to followup) | 26 (26.3%) | 25 (25.0%) | | BPAR ≥3 A | 16 (16.2%) | 21 (21.0%) | | Acute rejection associated with HDC | 3 (3.0%) | 4 (4.0%) | | Graft loss | 1 (1.0%) | 1 (1.0%) | | Death | 6 (6.1%) | 3 (3.0%) |
|
|
All differences were non-significant.
|
